Medication nonadherence among South American patients with schizophrenia
暂无分享,去创建一个
[1] G. Fond,et al. Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience , 2017, Social Psychiatry and Psychiatric Epidemiology.
[2] M. Sajatovic,et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness , 2017, Patient preference and adherence.
[3] Mercedes Hernandez,et al. Families and medication use and adherence among Latinos with schizophrenia , 2017, Journal of mental health.
[4] K. Baumstarck,et al. The relationships between patients’ and caregivers’ beliefs about the causes of schizophrenia and clinical outcomes in Latin American countries , 2015, Psychiatry Research.
[5] Yawen Jiang,et al. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization , 2015, Pharmacotherapy.
[6] R. Kahn,et al. Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies , 2015, European Neuropsychopharmacology.
[7] J. van der Vlag,et al. Role of Heparanase-Driven Inflammatory Cascade in Pathogenesis of Diabetic Nephropathy , 2014, Diabetes.
[8] J. Haro,et al. Relationship of Insight with Medication Adherence and the Impact on Outcomes in Patients with Schizophrenia and Bipolar Disorder: Results From A 1-Year European Outpatient Observational Study. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] K. Baumstarck,et al. Psychometric properties of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia , 2013, BMC Psychiatry.
[10] V. Milanova,et al. Attitudes Toward Antipsychotic Medication, Insight and Psychopathology in Outpatients with Schizophrenia , 2012, Folia medica.
[11] E. Lindström,et al. DAI-10 is as good as DAI-30 in schizophrenia , 2012, European Neuropsychopharmacology.
[12] J. Maurino,et al. Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder. , 2012, Patient preference and adherence.
[13] Rafael E. Núñez,et al. Facing the Sunrise: Cultural Worldview Underlying Intrinsic-Based Encoding of Absolute Frames of Reference in Aymara , 2012, Cogn. Sci..
[14] A. Loundou,et al. Insight into illness, neurocognition and quality of life in schizophrenia , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[15] O. Andreassen,et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder , 2012, Acta psychiatrica Scandinavica.
[16] B. Kleim,et al. Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication , 2011, Schizophrenia Research.
[17] Abraham Weizman,et al. Adherence to antipsychotic drug treatment in early-episode schizophrenia: A six-month naturalistic follow-up study , 2011, Schizophrenia Research.
[18] P. McGorry,et al. Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care , 2011, Current opinion in psychiatry.
[19] L. Boyer,et al. One or more durations of untreated psychosis? , 2011, Acta Psychiatrica Scandinavica.
[20] S. Bashir,et al. Association between Knowledge and Drug Adherence in Patients with Hypertension in Quetta, Pakistan , 2011 .
[21] J. Menzin,et al. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. , 2010, Psychiatric services.
[22] Robert Kohn,et al. Epidemiología de los trastornos mentales en América Latina y el Caribe , 2010 .
[23] L. Boyer,et al. Factors Associated with Medication Non-Adherence in Patients Suffering from Schizophrenia: A Cross-Sectional Study in a Universal Coverage Health-Care System , 2010 .
[24] P. Weiden,et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. , 2009, The Journal of clinical psychiatry.
[25] J. A. Sacristán,et al. [Treatment adherence and persistence: causes, consequences and improvement strategies]. , 2009, Atencion primaria.
[26] T. Gilmer,et al. Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency. , 2009, Psychiatric services.
[27] J. Lieberman,et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. , 2008, The Journal of clinical psychiatry.
[28] K. H. Gundermann,et al. Vigencia y desplazamiento de la lengua aymara en Chile , 2007 .
[29] A. Fu,et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States , 2007, Current medical research and opinion.
[30] R. Walden. Gender bias in research , 2007, Journal of the Royal Society of Medicine.
[31] A. Holdcroft. Gender bias in research: how does it affect evidence based medicine? , 2007, Journal of the Royal Society of Medicine.
[32] Jacqueline L Johnson,et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode , 2006, Schizophrenia Research.
[33] J. Lieberman,et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls , 2005, Schizophrenia Research.
[34] Alexander L. Miller,et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. , 2005, Schizophrenia bulletin.
[35] Robert Kohn,et al. Los trastornos mentales en América Latina y el Caribe: asunto prioritario para la salud pública , 2005 .
[36] H. Nicolini,et al. A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients , 2005, Schizophrenia Research.
[37] J. Suvisaari,et al. Age at onset and cognitive functioning in schizophrenia , 2004, British Journal of Psychiatry.
[38] R. Rasetti,et al. Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients. , 2004, The Journal of clinical psychiatry.
[39] F. P. Agraz,et al. Evaluación de actitudes al medicamento en pacientes con esquizofrenia: propiedades psicométricas de la versión en español del DAI , 2004 .
[40] Robert F. Reynolds,et al. Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia , 2004, The Journal of nervous and mental disease.
[41] S. De Geest,et al. Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.
[42] W. Fleischhacker,et al. Factors influencing compliance in schizophrenia patients. , 2003, The Journal of clinical psychiatry.
[43] Christian R. Dolder,et al. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia , 2003, Schizophrenia Research.
[44] S. Thomas,et al. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. , 2003, British journal of clinical pharmacology.
[45] Christian R. Dolder,et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. , 2002, The Journal of clinical psychiatry.
[46] M. Tohen,et al. Sex differences in clinical response to olanzapine compared with haloperidol , 2002, Psychiatry Research.
[47] A. Malla,et al. Duration of untreated psychosis: a critical examination of the concept and its importance , 2001, Psychological Medicine.
[48] C. Lançon,et al. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS) , 2000, Schizophrenia Research.
[49] M. Razali,et al. Compliance with treatment in schizophrenia: a drug intervention program in a developing country , 1995, Acta psychiatrica Scandinavica.
[50] T. Barnes. A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.
[51] J L Young,et al. Medication noncompliance in schizophrenia: codification and update. , 1986, The Bulletin of the American Academy of Psychiatry and the Law.
[52] T. Hogan,et al. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity , 1983, Psychological Medicine.
[53] G. Simpson,et al. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.
[54] Y. Bloch,et al. P-1278 - Rebelliousness in Patients Suffering From Schizophrenia-spectrum Disorders - a Possible Predictor of Adherence , 2012, European psychiatry.
[55] K. Zillmann. Putting gender on the agenda , 2010, Nature.
[56] X. Amador,et al. Poor insight in schizophrenia , 2005, Psychiatric Quarterly.
[57] P. Burkhart,et al. Adherence to long-term therapies: evidence for action. , 2003, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.
[58] W. Gaebel,et al. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. , 2001, Schizophrenia bulletin.
[59] W S Fenton,et al. Determinants of medication compliance in schizophrenia: empirical and clinical findings. , 1997, Schizophrenia bulletin.
[60] Jorge,et al. Etnografía : sociedades indígenas contemporáneas y su ideología , 1996 .
[61] R. Kessler,et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.
[62] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.